Montgomery Heart & Wellness
Houston, Texas, 77025, United States
NCT Number: NCT03172611
This study evaluates the effects of consuming a defined, plant-based diet on lipoprotein(a) and other atherogenic particles associated with cardiovascular disease risk.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Houston, Texas, 77025, United States
Lipoprotein(a) is a carrier of oxidized low-density lipoprotein and is a particularly atherogenic biomarker. Lp(a) has been previously documented to be resistant to dietary therapies and its concentration is thought to be determined by genes. A plant-based diet has not been previously used in an attempt to influence the concentration of Lp(a).
Participants were instructed to follow a defined, plant-based dietary intervention for four weeks. All animal products were excluded. Cooked foods, free oils, soda, alcohol, and coffee were also to be excluded. All meals and snacks were provided to the participants for the full duration of the intervention. Emphasized were raw fruits and vegetables, while seeds, avocado, raw oats, raw buckwheat, and dehydrated foods were prepared as condiments. Vitamin, herbal, and mineral supplements were to be discontinued unless otherwise clinically indicated. Participants were not advised to alter their exercise habits.
Serum biomarkers were obtained from participants at baseline and after 4-weeks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
Time frame: Baseline and 4-weeks
Serum Lp(a) (nmol/L) was documented at baseline and after 4-weeks
Time frame: Baseline and 4-weeks
Serum total cholesterol (mg/dL) was documented at baseline and after 4-weeks
Time frame: Baseline and 4-weeks
LDL cholesterol (mg/dL) was documented at baseline and after 4-weeks
Time frame: Baseline and 4-weeks
Serum HDL (mg/dL) was documented at baseline and after 4-weeks
Time frame: Baseline and 4-weeks
Serum Apo-B (mg/dL) was documented at baseline and after 4-weeks
Time frame: Baseline and 4-weeks
Serum LDL-P (nmol/L) was documented at baseline and after 4-weeks
Time frame: Baseline and 4-weeks
Serum sdLDL-C (mg/dL) was documented at baseline and after 4-weeks
Time frame: Baseline and 4-weeks
Serum HDL2-C (mg/dL) was documented at baseline and after 4-weeks
Time frame: Baseline and 4-weeks
Serum Apo A-1 (mg/dL) was documented at baseline and after 4-weeks
Texas Woman's University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737067
Arthrosclerosis, Dyslipidemias
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT05694260
Dyslipidemias, Hypercholesterolemia
Los Angeles, California, United States
View Trial DetailsNCT07655960
Dyslipidemia, Dyslipidemias
Seoul, South Korea
View Trial DetailsNCT02579655
Brain Diseases, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial Details